BP Plans to Exit $36 Billion Australian Green Hydrogen Project
The company told its partners in the Australian Renewable Energy Hub that it plans to leave the project as both operator and equity holder, according to a statement from a BP spokesperson. It's the latest setback for green hydrogen, a fuel once touted as a key way for Big Oil to profit from the energy transition but that has so far proved too costly for mass production and consumption.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sixth Street to acquire 38% stake in Sorgenia in $4.6bn deal
US-based investment company Sixth Street has agreed to acquire a 38% stake in Italian renewable energy company Sorgenia at an enterprise value of more than €4bn ($4.6bn). This investment by Sixth Street is part of a partnership with F2i, an Italian independent infrastructure fund manager. It will enable F2i to consolidate its energy transition assets under Sorgenia. As a result of the transaction, F2i will hold approximately 62% of Sorgenia. Predica, a subsidiary of Crédit Agricole Assurances, retains its minority interests in the F2i-owned companies, EF Solare and Renovalia Tramontana. Concurrently, Asterion Industrial Partners will exit Sorgenia's ownership structure. Asterion, an investment management company, made its initial investment in Sorgenia in 2020 and is now selling its 27.6% stake. The deal is pending customary regulatory approvals. F2i CEO Renato Ravanelli stated: 'With this transaction, F2i successfully reaches an important next step in a long and significant industrial growth journey in the energy sector. The development and consolidation of Sorgenia once again confirms F2i's ability to promote the growth of national and European-scale players in strategic sectors such as energy transition.' Sorgenia's portfolio now incorporates EF Solare, a photovoltaic operator in Italy, and Spanish renewable entities Renovalia and Renovalia Tramontana. Sorgenia currently operates 1.7GW of installed renewable capacity and plans to develop an additional 5GW. It also manages 4.4GW of gas-fired power plants critical for system stability during the energy transition, and provides retail services in electricity, gas, fibre connectivity and green technology to more than one million customers. This investment aligns with Sixth Street's strategy to support growth and development in the renewable sector across Italy and Spain. The consolidation aims to position Sorgenia as a leader in Europe's energy transition market. Sixth Street partner Richard Sberlati stated: 'This agreement establishes Sorgenia as one of the leading energy infrastructure platforms in Europe, and we're pleased to be collaborating with the F2i and Sorgenia teams on this transformational transaction. 'We look forward to contributing our solutions-oriented, patient institutional capital and deep energy infrastructure experience as we work together to facilitate the next phase of growth for the business.' "Sixth Street to acquire 38% stake in Sorgenia in $4.6bn deal" was originally created and published by Power Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
TechCrunch
an hour ago
- TechCrunch
Hacker used a voice phishing attack to steal Cisco customers' personal information
A cybercriminal tricked a Cisco representative into granting them access to steal the personal information of users, the company said on Tuesday. Cisco said it discovered the breach on July 24, blaming the incident on a voice phishing or 'vishing' call. The hackers accessed and exported 'a subset of basic profile information' from the database of a third party cloud-based customer relationship management (CRM) system, according to the company's disclosure. Cisco said that the stolen data included the customer's 'name, organization name, address, Cisco assigned user ID, email address, phone number, and account-related metadata,' such as the account creation date. The networking tech giant did not specify how many users were affected by the breach, and company spokespeople did not respond to that question when TechCrunch reached out on Tuesday. As Bleeping Computer noted, this breach could be another one in a string of attacks that targeted companies' Salesforce data, including U.S. insurance giant Allianz Life, luxury retailer Tiffany and Co., Australian airline Qantas, and others. Cisco is a known customer of Salesforce, according to the cloud giant.
Yahoo
an hour ago
- Yahoo
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
SYDNEY, AUSTRALIA, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and constructive feedback from the US Food and Drug Administration (FDA), regarding future clinical development of its first-in-class MHC Class II agonist, eftilagimod alfa ('efti'), for first line treatment of recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients who have PD-L1 expression below 1 (Combined Positive Score [CPS] <1). Based on its review of the encouraging data in 1L HNSCC with CPS <1 from the TACTI-003 (KEYNOTE-C34) Phase IIb trial evaluating efti in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab), the FDA agreed on the potential of efti in combination with KEYTRUDA to address the high unmet need in this CPS <1 patient segment and is supportive of the combination's further development. Paths for future clinical development and potential accelerated approval in light of the FDA's Project FrontRunner include a randomised registrational trial evaluating efti in combination with KEYTRUDA against standard-of-care therapy or alternatively a smaller single-arm study (e.g. 70 - 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomised study that builds on the existing data. 'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population,' said Marc Voigt, CEO of Immutep. 'Our primary focus clearly remains the pivotal TACTI-004 Phase III evaluating efti as first line therapy for non-small cell lung cancer and we are excited with its progress to date and the consistent, encouraging feedback we hear from physicians. This focus and additional considerations will be reviewed internally and discussed with stakeholders and potential strategic partners in regards to forward paths in head and neck cancer,' added Mr Voigt. Project FrontRunner is an FDA Oncology Center of Excellence (OCE) initiative to encourage drug sponsors to consider when it may be appropriate to develop and seek approval of cancer drugs for advanced/metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. In this setting, advancing new effective therapies has the greatest potential to significantly improve quantity and quality of patients' lives. Patients with CPS <1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS <1 and despite immunotherapy's progress in fighting cancer, anti-PD-1 therapy alone (without chemotherapy) is only approved for patients who express PD-L1 (CPS >1). All currently available treatment options for patients with PD-L1 CPS <1 include chemotherapy. About Immutep Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Investors/Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000;
